Chrystel Isca

Ospedale Sant Antonio

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Federico Piacentini

University of Modena and Reggio Emilia

Claudia Omarini

University of Modena and Reggio Emilia

Angela Toss

University of Modena and Reggio Emilia

Luca Moscetti

University of Modena and Reggio Emilia

Laura Cortesi

University of Modena and Reggio Emilia

Massimo Dominici

University of Modena and Reggio Emilia

Monica Barbolini

University of Modena and Reggio Emilia

Stefano Cascinu

IRCCS Ospedale San Raffaele

Elena Barbieri

University of Urbino

Isabella Sperduti

Istituti di Ricovero e Cura a Carattere Scientifico

Cooperative Institutions

University of Modena and Reggio Emilia

Policlinico di Modena

Istituti di Ricovero e Cura a Carattere Scientifico

University of Pisa

University of Florence

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Italian Oncology Group of Clinical Research

Azienda Unita' Sanitaria Locale Di Modena

University of Bologna

Azienda Ospedaliera Universitaria Pisana

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better?

Angela Toss Marta Venturelli Isabella Sperduti Chrystel Isca E. Barbieri

Source

Cite

Citations (0)

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

Cancers (2021)

Chrystel Isca Federico Piacentini Ilenia Mastrolia Valentina Masciale Federica Caggia

MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to investigate in vivo the mechanism of treatment resistance. In the management of human epidermal growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.

10.3390/cancers13194894

Cite

Citations (6)

The quality of palliative sedation in end-stage disease: audit from a department of oncology and haematology

Supportive Care in Cancer (2022)

Alessia Saviola Schipilliti Francesca Matilde Chrystel Isca Massimiliano Salati Daniele Dini

Pain medicine

10.1007/s00520-021-06730-8

Cite

Citations (2)

Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report

Immunotherapy (2022)

Lucia Trudu Giorgia Guaitoli Federica Bertolini Michela Maur Chiara Santini

Introduction: Aims of the study were to explore outcomes and toxicities of chemotherapy-immunotherapy (CT-IT) for patients (pts) with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) in a real-world population. Materials & methods: Clinical data of 26 pts with mNSCLC treated with CT-IT at our institution from January 2020 to January 2021 were collected retrospectively. Results: Median follow-up time was 7.7 months. Median progression-free survival was 9.5 months. The most frequent immune-related adverse event was thyroid dysfunction (ThD): 30.7%. Conclusion: There was a higher rate of ThD in this study population compared with the literature, with a possible correlation with clinical outcomes.

10.2217/imt-2021-0165

Cite

Citations (2)

The Quality of Palliative Sedation in End-Stage Disease: Audit From a Department of Oncology and Haematology

Research Square (Research Square) (2021)

Alessia Saviola Schipilliti Francesca Matilde Chrystel Isca Massimiliano Salati Daniele Dini

Abstract Purpose Palliative sedation (PS) plays a critical role to give suffering relief from refractory symptoms at the end of life. Our audit aimed to assess and improve quality of PS at the Department of Oncology and Hematology of University Hospital of Modena, to verify the adherence to international guidelines, the cooperation among members of care team, focusing with attention on family’s perception of this delicate situation. Methods From December 2016 to June 2019, data of patients undergoing PS in the Department were collected by an electronic folder tool, “Sedation Tool” (ST), that recorded clinical and PS informations, D-PaP, Rudkin Score and family’s perception. Results 245 patients were enrolled. 82% had a Karnofsky Performance Status 10-20%. The most common cancer types were lung and gastro-intestinal carcinomas (27% and 21% respectively). Refractory symptoms observed were confusion and agitation (76%), dyspnea (39%), pain (15%), delirium (10%), psychological distress (5%). Midazolam was the drug of choice for PS. Most of patients had Rudkin score 5 after 24 hours and 33% had terminal event within a period of 24 hours from the beginning of PS. During PS most of Patient’s relatives reported peacefulness (65%), agitation/impatience in 6% of cases, concern for suffering (16%). Conclusion PS is used in case of worsening general conditions at the end-stage disease to relieve refractory symptoms with dignity. The ST can become a simple instrument to evaluate and improve PS quality, providing more attention on the impact of PS on relatives to then possibly develop new supportive procedures for patients and their families.

Midazolam

Refractory (planetary science)

10.21203/rs.3.rs-1047987/v1

Cite

Citations (0)

Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center.

Monica Barbolini Claudia Omarini L. Viola Chrystel Isca Isabella Marchi

Center (category theory)

Source

Cite

Citations (0)

Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes

Biomarker Research (2025)

Claudia Omarini Virginia Catani Ilenia Mastrolia Angela Toss Federico Banchelli

Abstract Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. However, limited knowledge exists on the levels and clinical meaning of miR-21 in extracellular vesicles (EVs) of patients with breast cancer (BC). We assessed EV-derived miR-21 levels in one hundred women: 30 with early BC (EBC), 30 with metastatic BC on treatment progression (MBC), 30 cancer survivors on follow-up (FU) and 10 healthy donors (HD) as age- and body mass index (BMI)-matched controls. EVs isolated from serum samples were characterized using nanoparticle tracking analysis, scanning electron microscopy and atomic force microscopy to detect their concentration, size, morphology and mechanical properties. The levels of miR-21 in EVs was evaluated using real time PCR and compared between groups (EBC, MBC and FU vs. HD) by calculating the fold change and ΔΔCt statistic. EVs size and concentration did not differ significantly among patient groups. In the EBC group, the clinical stage at diagnosis and tumor subtype did not influence miR-21 levels. The levels of miR-21 were higher in the MBC group than in the HD group ( p = 0.029), mainly in those who were human epidermal growth factor receptor 2 (HER2)+ ( p = 0.0005) and hormone receptor-positive ( p = 0.036). In particular, in the HER2 + subgroup, the miR-21 levels were significantly higher in those with active BC (both EBC and MBC) than in HDs ( p = 0.002). Our findings suggest that miR-21 may be a promising biomarker for diagnosis and tumor activity, mainly in HER2 + BC.

Extracellular Vesicles

Nanoparticle tracking analysis

10.1186/s40364-025-00724-y

Cite

Citations (0)

Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients.

Silvia Pozzi L. Belletti Laura Cortesi Luca Moscetti Claudia Omarini

Center (category theory)

Source

Cite

Citations (0)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

ESMO Open (2021)

Marzia Del Re Claudia Omarini Lucrezia Diodati Michela Palleschi Icro Meattini

Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH-dependent solubility and potential drug-drug interaction at the absorption level may affect clinical pharmacokinetics. The current study was aimed at investigating the effect of co-administration of PPIs and palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.Patients affected by estrogen receptor-positive, human epidermal growth factor receptor 2-negative mBC, who were candidates for first-line treatment with palbociclib, were enrolled in this retrospective observational study. Patients were defined as 'no concomitant PPIs' if no PPIs were administered during palbociclib treatment, and as 'concomitant PPIs' if the administration of PPIs covered the entire or not less than two-thirds of treatment with palbociclib. All clinical interventions were made according to clinical practice.A total of 112 patients were enrolled in the study; 56 belonged to the 'no concomitant PPIs' group and 56 to the 'concomitant PPIs' group. Seventy-one patients were endocrine-sensitive and received palbociclib and letrozole, and 43 were endocrine-resistant and were treated with palbociclib and fulvestrant. The most prescribed PPI was lansoprazole. Patients taking PPIs had a shorter PFS than those taking palbociclib and endocrine therapy alone (14.0 versus 37.9 months, P < 0.0001). Multivariate analysis confirmed concomitant PPIs as the only independent predictive factor for shorter PFS (P = 0.0002). PFS was significantly longer in estrogen-sensitive mBC with no concomitant PPIs compared with patients taking PPIs or estrogen-resistant patients, with and without PPIs (P < 0.0001). No correlation with adverse events was found when considering grade >2 hematological toxicities [Common Terminology Criteria for Adverse Events (CTCAE) scale].The present study demonstrates that concomitant use of PPIs in mBC patients treated with palbociclib has a detrimental effect on PFS. Therefore, it is recommended to prescribe PPIs with caution in these patients, strictly adhering to the indications in the summary of product characteristics (RCP).

Palbociclib

Concomitant

Fulvestrant

Rabeprazole

10.1016/j.esmoop.2021.100231

Cite

Citations (43)

Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status

Journal of Cancer Research and Clinical Oncology (2019)

Claudia Omarini Stefania Bettelli Cecilia Caprera Samantha Manfredini Monica Barbolini

Hematology

10.1007/s00432-018-02833-8

Cite

Citations (5)